Cases & Deals

Isis Pharmaceuticals establishes patent portfolio for antisense oligonucleotides directed to IL-4R alpha

Clients Isis Pharmaceuticals, Inc.

Jones Day assisted Isis Pharmaceuticals, Inc. in the development of a global patent portfolio related to antisense oligonucleotides and other oligomeric compounds that target interleukin-4 receptor alpha (IL-4Ra), as well as uses of those compounds for the prevention and treatment of various conditions associated with expression of IL-4Ra, such as pulmonary inflammation and airway hyperresponsiveness.